Further studies will be needed to evaluate whether inhibitors of the IL-17 pathway (e.g., IL-17A, IL-17A/IL-17F, and IL-23A) could be used to treat the pemphigus group of blistering diseases in humans and dogs. The gene discussed is IL23A; the disease is pemphigus.